Q1 EPS Estimates for Sanara MedTech Lowered by HC Wainwright

Sanara MedTech Inc. (NASDAQ:SMTI) – Equities research analysts at HC Wainwright cut their Q1 2025 EPS estimates for shares of Sanara MedTech in a report released on Wednesday, March 26th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.31) per share for the quarter, down from their previous estimate of ($0.26). HC Wainwright currently has a “Buy” rating and a $51.00 target price on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Sanara MedTech’s Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($1.12) EPS.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $46.00 price target on shares of Sanara MedTech in a research report on Wednesday.

Sanara MedTech Stock Up 5.4 %

Shares of SMTI opened at $31.22 on Friday. The company’s 50-day moving average price is $34.31 and its 200 day moving average price is $33.77. Sanara MedTech has a 12-month low of $26.00 and a 12-month high of $39.08. The company has a current ratio of 2.23, a quick ratio of 2.02 and a debt-to-equity ratio of 0.76. The firm has a market cap of $272.89 million, a P/E ratio of -31.54 and a beta of 1.37.

Sanara MedTech (NASDAQ:SMTI) last posted its earnings results on Tuesday, March 25th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. The company had revenue of $26.31 million for the quarter, compared to the consensus estimate of $22.75 million. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%.

Institutional Investors Weigh In On Sanara MedTech

A number of institutional investors have recently modified their holdings of SMTI. State Street Corp lifted its stake in Sanara MedTech by 9.2% during the 3rd quarter. State Street Corp now owns 58,688 shares of the company’s stock worth $1,775,000 after acquiring an additional 4,932 shares in the last quarter. Barclays PLC lifted its position in shares of Sanara MedTech by 323.0% during the third quarter. Barclays PLC now owns 5,731 shares of the company’s stock worth $174,000 after purchasing an additional 4,376 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Sanara MedTech by 4.4% in the third quarter. Geode Capital Management LLC now owns 88,271 shares of the company’s stock valued at $2,670,000 after purchasing an additional 3,755 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Sanara MedTech by 127.2% in the third quarter. JPMorgan Chase & Co. now owns 4,058 shares of the company’s stock valued at $123,000 after purchasing an additional 2,272 shares during the period. Finally, Fifth Third Bancorp acquired a new position in shares of Sanara MedTech in the fourth quarter valued at approximately $898,000. 8.10% of the stock is owned by institutional investors and hedge funds.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.